| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| No Relationships to Disclose |
|
|
| Honoraria |
| Company: Boehringer Ingelheim |
| Recipient: You |
|
| Consulting or Advisory Role |
| Company: Pfizer |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: AstraZeneca |
| Recipient: You |
| Company: Lucence |
| Recipient: You |
| Company: Merck Sharp & Dohme |
| Recipient: Your Institution |
| Company: EMD Serono |
| Recipient: Your Institution |
| Company: AstraZeneca |
| Recipient: Your Institution |
| Company: Blueprint Medicines |
| Recipient: Your Institution |
| Company: Tesaro |
| Recipient: Your Institution |
| Company: Bavarian Nordic |
| Recipient: Your Institution |
| Company: NOVARTIS |
| Recipient: Your Institution |
| Company: G1 Therapeutics |
| Recipient: Your Institution |
| Company: adaptimmune |
| Recipient: Your Institution |
| Company: BMS |
| Recipient: Your Institution |
| Company: GSK |
| Recipient: Your Institution |
| Company: Abbvie |
| Recipient: Your Institution |
| Company: Rgenix |
| Recipient: Your Institution |
| Company: Pfizer |
| Recipient: Your Institution |
| Company: Roche |
| Recipient: Your Institution |
| Company: Genentech |
| Recipient: Your Institution |
| Company: Lilly |
| Recipient: Your Institution |
| Company: Janssen |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| No Relationships to Disclose |
|
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| Company: Boehringer Ingelheim |
| Recipient: You |
| Company: Pfizer |
| Recipient: You |
| Company: E.R. Squibb Sons, LLC |
| Recipient: You |
| Company: Janssen |
| Recipient: You |
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| not answered |
|
|
| (OPTIONAL) Open Payments Link |
| not answered |
|
|